Supriya Lifescience Ltd, a cGMP-certified leader in the manufacturing of Active Pharmaceutical Ingredients (APIs), has been honoured by the Government of Maharashtra with the Maharashtra State Export Award for its remarkable export achievements in the financial years 2022–23 and 2023–24. The award was presented to Dr Satish Wagh, Executive Chairman & Whole-Time Director, and Dr Saloni Wagh, Managing Director, by Hon’ble Uday Samant, Minister of Industries & Marathi Language; P Anbalagan (IAS), Secretary (Industries); and Deependra Singh Kushwah (IAS), Development Commissioner (Industries) & Commissioner (Exports), during a ceremony held at Taj Lands’ End, Mumbai, on October 13, 2025.
This recognition underscores Supriya Lifescience’s continued excellence in pharmaceutical exports and its role in strengthening India’s reputation as a trusted global healthcare partner. With operations spanning over 120 countries, the company has built a diverse product portfolio encompassing APIs, Finished Dosage Forms (FDFs), and Contract Development and Manufacturing (CDMO) services. Its fully integrated manufacturing infrastructure, combined with a steadfast focus on quality and regulatory compliance, has been key to its sustained global growth.
Expressing his gratitude, Dr Satish Wagh stated, “It is a great privilege to receive the Maharashtra State Export Award for two successive years. This honour reflects our commitment to maintaining the highest global quality standards, driving innovation, and ensuring that safe, reliable, and affordable pharmaceutical products reach patients worldwide. It is also a tribute to the dedication of our team and our valued partners who continue to support our mission of improving global healthcare access.”
Adding to his remarks, Dr Saloni Wagh said, “This award further strengthens our resolve to pursue sustainable and ethical growth while deepening our scientific and technological capabilities. It motivates us to expand our research-led initiatives and reinforce Maharashtra’s leadership in industrial development, contributing to India’s aspiration of being a trusted global healthcare hub.”
Supriya Lifescience remains focused on expanding its export footprint, enhancing innovation, and reinforcing India’s position as a leading force in the global pharmaceutical industry. Established in 1987, Supriya Lifescience Ltd is a globally recognized manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates. Headquartered in Mumbai, with a state-of-the-art manufacturing facility at Khed, District Ratnagiri, the company holds certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA, among others.
Its world-class infrastructure—compliant with EMA, US FDA, WHO, PMDA, TGA, KFDA, and ANVISA standards—is backed by a robust R&D division, eight active CEPs, and fourteen active USDMFs. Guided by strong ethical values and environmental sustainability principles, Supriya Lifescience continues to support innovators and generic manufacturers worldwide through its API, intermediate, and CMO partnerships.
